Tag Archive for: INKEF

Can private markets continue to drive development in Life Sciences? – Insights from Optimum’s Healthcare Conference

We were proud to host a fantastic panel chaired by BioCentury’s European Editor Stephen Hansen with Soren Moller, Managing Partner of Novo Seeds; Karin Kleinhans, Partner of MRL Ventures Fund; Hakan Goker, Managing Director of M Ventures; Roel Bulthuis, Managing Partner at Inkef. This panel of Venture Capital (VC) investors discussed the strength of private […]

An Overview of Optimum’s 14th Annual Healthcare Investor Conference 2022

Two weeks ago, Optimum hosted its 14th Annual Healthcare Investor Conference and wow, what a fantastic event it was! After two years of disruption, we were delighted to be meeting again in person. While virtual meetings have been a fantastic boon during these difficult times, nothing can beat meeting and sharing ideas and opinions face-to-face, […]

Precirix raises EUR 80m in Series B to advance its pipeline of precision radiopharmaceuticals

Precirix NV, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology, today announces the closing of a EUR 80m Series B financing round led by new investors INKEF Capital, Jeito Capital and Forbion as co-leads. Read more

Investor Q&A Series: Roel Bulthuis, INKEF Capital

In our first Investor Q&A article, Roel Bulthuis, Managing Partner of INKEF Capital shares his thoughts on the investment landscape in Europe.

Accessing European Investment in a Post Covid-19 World

A video panel by Optimum in partnership with One Nucleus for ON Helix event held virtually in July 2020